Insider Sell: Atreca
5:47PM ET 9/28/2021 MT NewswiresTito Serafini, Director, Chief Strategy Officer, on September 27, 2021, sold 30,000 shares in Atreca (BCEL) for $197,541. Following the Form 4 filing with...
Quotes Snapshot > BCEL
Atreca Inc BCEL:NASDAQ
Last Price$2.87NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.97 (5)
Ask (Size)$3.00 (3)
Day Low / HighN/A - N/A
Volume1.3 M
Read more news Recent News
--Wedbush Adjusts Atreca's Price Target to $12 From $27; Outperform Rating Kept
6:50AM ET 7/30/2021 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Sector Update: Health Care Stocks Closing Slightly Higher
4:05PM ET 7/29/2021 MT NewswiresHealth care stocks were slightly higher late in Thursday's session, with the NYSE Health Care Index rising 0.2% while the Health Care Select Sector SPDR...
Sector Update: Health Care
3:44PM ET 7/29/2021 MT NewswiresHealth care stocks continue to edge higher late in Thursday trading, with the NYSE Health Care Index rising 0.2% while the SPDR Health Care Select Sector...
View all Commentary and Analysis
Atreca Is A Unique Biotech With Key Data Readouts In Coming Years
5:15PM ET 11/12/2021 Seeking AlphaTracking Baker Brothers Portfolio - Q2 2021 Update
12:54AM ET 10/05/2021 Seeking AlphaAtreca: Safety Data Brought Down Stock
5:31PM ET 9/10/2021 Seeking AlphaAtreca (BCEL) Investor Presentation - Slideshow
11:49AM ET 8/13/2021 Seeking AlphaCompany Profile
Business DescriptionAtreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA. View company web site for more details
| Address | 835 Industrial Road San Carlos, California 94070 |
| Phone | +1.650.595.2595 |
| Number of Employees | 85 |
| President, Chief Executive Officer & Director | John A. Orwin |
| Chief Financial Officer | Herbert C. Cross |
| Senior Vice President-Research | Daniel Emerling |
| SVP-Informatics & Information Technology | Wayne Volkmuth |
Company Highlights
| Price Open | $3.70 |
| Previous Close | $3.71 |
| 52 Week Range | $2.85 - 20.29 |
| Market Capitalization | $87.3 M |
| Shares Outstanding | 30.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/24/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.79 |
| Beta vs. S&P 500 | N/A |
| Revenue | $961.0 K |
| Net Profit Margin | -8,448.23% |
| Return on Equity | -49.11% |
Analyst Ratings as of 07/28/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |